Exemestane plus ovarian function suppression is the best adjuvant treatment of premenopausal women with endocrine-responsive breast cancer at higher risk of relapse and with her2-negative tumors

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)1838-1840
Number of pages3
JournalJournal of Clinical Oncology
Issue number21
Publication statusPublished - Jul 20 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this